Context Therapeutics, a clinical-stage biopharmaceutical company dedicated to the treatment of hormone-responsive cancers, today announced two key additions to its board of directors. 

Deepak Lala, Tasir Haque, Hannah Feinman, Jianhong Wu, Yuren Wang, Amy Dwyer, Thu Truong and Carol Lange

Context Therapeutics, a clinical-stage biotechnology company, today announced that new preclinical data on Apristor®, its first-in-class full progesterone receptor antagonist, will be featured at the San Antonio Breast Cancer Symposium® taking place on December 4-8, 2018 in San Antonio, TX.